CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY(R) (SUGEMALIMAB)...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SUZHOU, China, Dec. 21, 2021 /PRNewswire-AsiaNet/ -- CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China has approved the new drug application ("NDA") of anti-PD-L1 monoclonal antibody Cejemly(R) (sugemalimab) ...
Authors: LATEST ASIANET NEWS RELEASES